Earnings Preview: Bristol-Myers Squibb and Celgene Corporation

Celgene and Bristol-Myers Squibb are set to report second quarter earnings this week. Here's what investors need to know.

Jul 23, 2014 at 2:00PM

Most health care stocks have been experiencing a roller coaster ride so far this year. While the underlying cause(s) of this volatility is likely multifaceted in nature, I think a fair amount is attributable to the uncertain outlook regarding some of the top names in the sector. 

Bristol-Myers Squibb (NYSE:BMY) and Celgene Corp. (NASDAQ:CELG) are two closely watched names that nicely illustrate the market's love-hate relationship with health care this year, shown by the chart below. With both companies releasing earnings for the second quarter this week, let's take a look at the key issues that may help to either feed --or perhaps quell, this volatility moving forward.   

BMY Chart

BMY data by YCharts

Bristol-Myers will report on Thursday before the bell
Shares of Bristol-Myers have now fallen close to 8% for the year. While this lackluster performance is probably due to stagnate growth and falling revenues, the company's clinical pipeline has also had its fair share of disappointments this year as well.

For the second quarter, the Street is looking for Bristol to post non-GAAP EPS of $0.44 on $3.85 billion in revenue. What's key to understand is that this would represent flat EPS growth year over year and a 4.9% decline in revenue.

Bristol has been able to hold its EPS steady primarily by lowering its marketing, selling, and administrative expenses through a general restructuring process. After the recent acquisition of iPierian, the continued expansion of its clinical activities and research collaboration with Five Prime Therapeutics, and gearing up to launch its hepatitis C drug, I think operating costs will be a key issue to keep tabs on this quarter.

Keeping with this idea, the Street is expecting EPS to decline this quarter, compared to the first quarter, by 4.3%. On the bright side, Bristol has seen stellar top-line growth for a number of key pharma products lately, including Sprycel, Yervoy, Orencia and Baraclude. Put simply, these particular products could help offset rising costs.

On the clinical side, investors should be on the lookout for updates on the regulatory filings for Bristol's PD-1 inhibitor nivolumab. Per the last update, nivolumab was scheduled to be under review as a treatment for advanced melanoma by the third quarter. The company also has a rolling submission application in the works for nivolumab as a treatment for non-small cell lung cancer. 

Celgene reports Thursday before the bell
Celgene is looking to follow-up its first-quarter earnings beat come Thursday. However, that may be difficult to achieve given the lofty expectations the Street has this quarter.

The Street is looking for non-GAAP EPS to come in at $0.89 on $1.85 billion in revenue for the second quarter. Consensus thus represents a healthy 6.5% increase in quarter over quarter EPS, propelled mainly by a 6.9% rise in revenue. 

That being said, Revlimid and Abraxane's stellar sales growth in recent quarters are two very good reasons to believe these projections may not be far off the mark. Given Abraxane's recent label expansion as a treatment for advanced pancreatic cancer, we should see the drug continue its rapid sales growth this quarter, making it a key drug in Celgene's portfolio to watch. Pomalyst has also seen sales grow in a big way as of late, which could be the basis of an upside surprise this quarter.

Foolish wrap-up
Bristol is undoubtedly a company in transition. Nonetheless, it does have a number of irons in the fire, with the goal of creating top-line growth going forward. With over $3 billion in net cash, I think we'll end up seeing Bristol play the M&A game again this year in the hopes of accelerating this process. Nivolumab's steady progress toward a regulatory approval also gives the company a realistic shot at adding another megablockbuster to its product portfolio in the near future. Simply put, Bristol may be close to turning the corner, making it a compelling name to watch this earnings season. 

Celgene, on the other hand, is a red hot biotech that has repeatedly posted impressive revenue numbers -- even beating already optimistic estimates by Wall Street. On Thursday, I wouldn't be surprised to see Celgene will continue this trend, driven mainly by stronger than expected sales of Abraxane. 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

 

George Budwell has no position in any stocks mentioned. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers